22Nd Cent (XXII) 1.12 $XXII
22nd Century Announces Expansion of Cannabis Research Program
BusinessWire - Tue Sep 06, 9:00AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that the Company's wholly-owned subsidiary, Botanical Genetics LLC, has expanded its cannabis research program to include multiple new research projects in support of its core mission, which is to develop proprietary cannabis strains for important new medicines and commercially viable agricultural crops. More specifically, Botanical Genetics is: 1) working to develop proprietary cannabis strains for novel, safe, and effective medical applications, and 2) developing very low THC industrial hemp varieties that may be legally grown in the U.S. and around the world as a commercial agricultural crop.
XXII: 1.12 (+0.02)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.12 (+0.02), PTCT: 10.99 (+1.88), GRFS: 16.08 (+0.08), PBYI: 58.95 (-0.51)
Gilla Increases Margins by 25% While Continuing to Win Awards
ACCESSWIRE - Thu Aug 18, 8:00AM CDT
KALISPELL, MT / ACCESSWIRE / August 18, 2016 / Gilla Inc. (OTCQB: GLLA), the fast-growing designer, manufacturer and marketer of E-liquid for vaporizers, recently announced their Q2 2016 results. In the filing, significant improvements were made in gross margins, as they jumped from 37% in Q1 2016 to 62% this quarter. This is partly attributable to a higher percentage of sales being from their own product portfolio of premium E-liquid products.
PM: 98.82 (-0.02), XXII: 1.12 (+0.02), MO: 62.72 (-0.08)
Production of Industrial Hemp to Dramatically Increase as Demand for Eco-Friendly Natural Fiber Continues to Rise
PR Newswire - Wed Aug 10, 7:45AM CDT
Industrial hemp known as a hardy and renewable resource (one of the earliest domesticated plants known) is quickly becoming a required resource for various industrial applications, including paper, textiles, and cordage. Sustainable hemp seed, fiber and oil are being used in raw materials by major companies, including Ford Motors, Patagonia, and The Body Shop, to make a wide variety of products as a few select Hemp manufacturers race to increase operations as the demand continues to grow.
XXII: 1.12 (+0.02)
22nd Century Group Files 2016 Second Quarter Report Announces Conference Call to Provide Business Update
BusinessWire - Tue Aug 09, 3:15PM CDT
22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, today released the Company's second quarter 2016 financial results and announced that it will provide a business update for investors on a conference call to be held on Wednesday, August 10th, at 4:00 PM (Eastern Time).
XXII: 1.12 (+0.02)
22nd Century Group (XXII) Catches Eye: Stock Rises 7.8%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:31AM CDT
22nd Century Group, Inc. (XXII) shares rose almost 8% in the last trading session.
XXII: 1.12 (+0.02), ANIP: 63.75 (-0.55)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 1.12 (+0.02), GWPH: 105.41 (+0.29)
Which Stocks To Watch Ahead Of The Potential Us-Wide Federal Legalization Of Medical Cannabis
ACCESSWIRE - Mon Jun 20, 4:15PM CDT
WINDSOR, ON / ACCESSWIRE / June 20, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to alert investors about a huge upcoming catalyst in the marijuana industry as well as stocks to watch out for once the news hits the press.
XXII: 1.12 (+0.02)
22nd Century's Proprietary SPECTRUM(R) Cigarettes Identified as Crucial Tool in Human Addiction Studies
BusinessWire - Thu Jun 16, 8:44AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that scientists with The Centers for Disease Control and Prevention (CDC) published a detailed characterization of the Company's SPECTRUM(R) Variable Nicotine Research Cigarettes, calling 22nd Century's proprietary cigarettes an "important tool in clinical studies for investigating... the impact of reduced nicotine cigarettes on nicotine addiction..." Published in Tobacco Regulatory Science, the independent study was conducted by a prestigious team of 18 senior CDC scientists. Click here for a link to the complete article.
XXII: 1.12 (+0.02)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 1.12 (+0.02), CARA: 6.87 (+0.37), GWPH: 105.41 (+0.29)
Demand Continues to Surge for Cannabis & Industrial Hemp Products While Becoming a Cornerstone for Financial Stability for Growers & Processing Facilities
PR Newswire Europe - Tue Jun 07, 12:28PM CDT
CORAL SPRINGS, Florida, June 7, 2016 /PRNewswire/ --
XXII: 1.12 (+0.02)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 1.12 (+0.02), CARA: 6.87 (+0.37), GWPH: 105.41 (+0.29)
Cannabis & Legal Marijuana Sector Continues To See Steady Growth As Companies Launch Newest Innovative Products; Company to Develop First Ever MMJ Plant to Paper Product
PR Newswire - Wed Jun 01, 7:30AM CDT
As legal & medical marijuana uses evolves and becomes more accepted in US society, companies continue to push the industry forward with increased research and the development of new products and services. With Legal Marijuana Sales expected to top $20 Billion within five years, innovative and emerging MMJ/Cannabis companies in the sector race to develop newest products for states currently online with production and sales.
CARA: 6.87 (+0.37), XXII: 1.12 (+0.02)
22nd Century Presents at Hofstra Northwell School of Medicine; Reveals New Initiative to Engage Health Care Professionals
BusinessWire - Fri May 27, 8:22AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on May 26, 2016, Paul J. Rushton, Ph.D., the Company's Vice President of Plant Biotechnology, gave a seminar to discuss 22nd Century's novel Very Low Nicotine smoking cessation aid at Hofstra Northwell School of Medicine on the campus of Hofstra University in Hempstead, New York.
XXII: 1.12 (+0.02)
Could the World's Most Effective Quit Smoking Aid be a Low Nicotine Cigarette? US Public Health Officials Think So
ACCESSWIRE - Wed May 25, 8:39AM CDT
More Than 16 Million Americans Attempt To Quit Smoking Each Year without the Use of Drugs or Therapies--And Only 2-5% Successfully Quit In A Given Year; 22nd Century Group (NYSE MKT: XXII) Is Developing the Most Effective Solution to Date for These "Marooned" Consumers
PM: 98.82 (-0.02), XXII: 1.12 (+0.02), PFE: 33.65 (-0.29), GSK: 43.30 (+0.42)
22nd Century Launches MAGIC 0 Very Low Nicotine Cigarettes in France
BusinessWire - Wed May 25, 7:30AM CDT
22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the receipt of an initial purchase order for MAGIC 0 Very Low Nicotine cigarettes from French distributor, Royal Distribution. Beginning in June, Royal Distribution will promote and sell the MAGIC brand in France as the world's lowest nicotine tobacco cigarette. Before the end of 2016, Royal Distribution projects it will have placed MAGIC 0 cigarettes in more than 750 tobacco stores throughout France.
XXII: 1.12 (+0.02)
Independent Phase II and III Clinical Studies on 22nd Century's Smoking Cessation Technology Highlighted on New Heracles Website
BusinessWire - Tue May 24, 9:23AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website at www.heraclespharma.com to highlight the Company's X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22 is the first and only smoking cessation product in the form of a combustible cigarette. X-22 smokes, tastes and smells like a regular cigarette but is, based on independent clinical studies, exceptionally effective as a smoking cessation product. With the goal of ultimately commercializing X-22 as a prescription-based pharmaceutical product, 22nd Century's wholly-owned subsidiary, Heracles Pharmaceuticals, is the only company in the world with an active IND (Investigational New Drug) application with the FDA for a combustible cigarette as a smoking cessation product.
XXII: 1.12 (+0.02)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT" , an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process.
RAI: 47.38 (+0.07), PM: 98.82 (-0.02), BTI: 123.75 (+0.55), XXII: 1.12 (+0.02), MO: 62.72 (-0.08), ARDM: 5.19 (+0.10), OMER: 11.34 (+0.06)
22nd Century Announces Expansion of Cannabis Research Program
BusinessWire - Tue Sep 06, 9:00AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that the Company's wholly-owned subsidiary, Botanical Genetics LLC, has expanded its cannabis research program to include multiple new research projects in support of its core mission, which is to develop proprietary cannabis strains for important new medicines and commercially viable agricultural crops. More specifically, Botanical Genetics is: 1) working to develop proprietary cannabis strains for novel, safe, and effective medical applications, and 2) developing very low THC industrial hemp varieties that may be legally grown in the U.S. and around the world as a commercial agricultural crop.
XXII: 1.12 (+0.02)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.12 (+0.02), PTCT: 10.99 (+1.88), GRFS: 16.08 (+0.08), PBYI: 58.95 (-0.51)
Gilla Increases Margins by 25% While Continuing to Win Awards
ACCESSWIRE - Thu Aug 18, 8:00AM CDT
KALISPELL, MT / ACCESSWIRE / August 18, 2016 / Gilla Inc. (OTCQB: GLLA), the fast-growing designer, manufacturer and marketer of E-liquid for vaporizers, recently announced their Q2 2016 results. In the filing, significant improvements were made in gross margins, as they jumped from 37% in Q1 2016 to 62% this quarter. This is partly attributable to a higher percentage of sales being from their own product portfolio of premium E-liquid products.
PM: 98.82 (-0.02), XXII: 1.12 (+0.02), MO: 62.72 (-0.08)
Production of Industrial Hemp to Dramatically Increase as Demand for Eco-Friendly Natural Fiber Continues to Rise
PR Newswire - Wed Aug 10, 7:45AM CDT
Industrial hemp known as a hardy and renewable resource (one of the earliest domesticated plants known) is quickly becoming a required resource for various industrial applications, including paper, textiles, and cordage. Sustainable hemp seed, fiber and oil are being used in raw materials by major companies, including Ford Motors, Patagonia, and The Body Shop, to make a wide variety of products as a few select Hemp manufacturers race to increase operations as the demand continues to grow.
XXII: 1.12 (+0.02)
22nd Century Group Files 2016 Second Quarter Report Announces Conference Call to Provide Business Update
BusinessWire - Tue Aug 09, 3:15PM CDT
22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, today released the Company's second quarter 2016 financial results and announced that it will provide a business update for investors on a conference call to be held on Wednesday, August 10th, at 4:00 PM (Eastern Time).
XXII: 1.12 (+0.02)
22nd Century Group (XXII) Catches Eye: Stock Rises 7.8%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:31AM CDT
22nd Century Group, Inc. (XXII) shares rose almost 8% in the last trading session.
XXII: 1.12 (+0.02), ANIP: 63.75 (-0.55)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 1.12 (+0.02), GWPH: 105.41 (+0.29)
Which Stocks To Watch Ahead Of The Potential Us-Wide Federal Legalization Of Medical Cannabis
ACCESSWIRE - Mon Jun 20, 4:15PM CDT
WINDSOR, ON / ACCESSWIRE / June 20, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to alert investors about a huge upcoming catalyst in the marijuana industry as well as stocks to watch out for once the news hits the press. XXII: 1.12 (+0.02)
22nd Century's Proprietary SPECTRUM(R) Cigarettes Identified as Crucial Tool in Human Addiction Studies
BusinessWire - Thu Jun 16, 8:44AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that scientists with The Centers for Disease Control and Prevention (CDC) published a detailed characterization of the Company's SPECTRUM(R) Variable Nicotine Research Cigarettes, calling 22nd Century's proprietary cigarettes an "important tool in clinical studies for investigating... the impact of reduced nicotine cigarettes on nicotine addiction..." Published in Tobacco Regulatory Science, the independent study was conducted by a prestigious team of 18 senior CDC scientists. Click here for a link to the complete article.
XXII: 1.12 (+0.02)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 1.12 (+0.02), CARA: 6.87 (+0.37), GWPH: 105.41 (+0.29)
Demand Continues to Surge for Cannabis & Industrial Hemp Products While Becoming a Cornerstone for Financial Stability for Growers & Processing Facilities
PR Newswire Europe - Tue Jun 07, 12:28PM CDT
CORAL SPRINGS, Florida, June 7, 2016 /PRNewswire/ --
XXII: 1.12 (+0.02)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 1.12 (+0.02), CARA: 6.87 (+0.37), GWPH: 105.41 (+0.29)
Cannabis & Legal Marijuana Sector Continues To See Steady Growth As Companies Launch Newest Innovative Products; Company to Develop First Ever MMJ Plant to Paper Product
PR Newswire - Wed Jun 01, 7:30AM CDT
As legal & medical marijuana uses evolves and becomes more accepted in US society, companies continue to push the industry forward with increased research and the development of new products and services. With Legal Marijuana Sales expected to top $20 Billion within five years, innovative and emerging MMJ/Cannabis companies in the sector race to develop newest products for states currently online with production and sales.
CARA: 6.87 (+0.37), XXII: 1.12 (+0.02)
22nd Century Presents at Hofstra Northwell School of Medicine; Reveals New Initiative to Engage Health Care Professionals
BusinessWire - Fri May 27, 8:22AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on May 26, 2016, Paul J. Rushton, Ph.D., the Company's Vice President of Plant Biotechnology, gave a seminar to discuss 22nd Century's novel Very Low Nicotine smoking cessation aid at Hofstra Northwell School of Medicine on the campus of Hofstra University in Hempstead, New York.
XXII: 1.12 (+0.02)
Could the World's Most Effective Quit Smoking Aid be a Low Nicotine Cigarette? US Public Health Officials Think So
ACCESSWIRE - Wed May 25, 8:39AM CDT
More Than 16 Million Americans Attempt To Quit Smoking Each Year without the Use of Drugs or Therapies--And Only 2-5% Successfully Quit In A Given Year; 22nd Century Group (NYSE MKT: XXII) Is Developing the Most Effective Solution to Date for These "Marooned" Consumers
PM: 98.82 (-0.02), XXII: 1.12 (+0.02), PFE: 33.65 (-0.29), GSK: 43.30 (+0.42)
22nd Century Launches MAGIC 0 Very Low Nicotine Cigarettes in France
BusinessWire - Wed May 25, 7:30AM CDT
22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the receipt of an initial purchase order for MAGIC 0 Very Low Nicotine cigarettes from French distributor, Royal Distribution. Beginning in June, Royal Distribution will promote and sell the MAGIC brand in France as the world's lowest nicotine tobacco cigarette. Before the end of 2016, Royal Distribution projects it will have placed MAGIC 0 cigarettes in more than 750 tobacco stores throughout France.
XXII: 1.12 (+0.02)
Independent Phase II and III Clinical Studies on 22nd Century's Smoking Cessation Technology Highlighted on New Heracles Website
BusinessWire - Tue May 24, 9:23AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website at www.heraclespharma.com to highlight the Company's X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22 is the first and only smoking cessation product in the form of a combustible cigarette. X-22 smokes, tastes and smells like a regular cigarette but is, based on independent clinical studies, exceptionally effective as a smoking cessation product. With the goal of ultimately commercializing X-22 as a prescription-based pharmaceutical product, 22nd Century's wholly-owned subsidiary, Heracles Pharmaceuticals, is the only company in the world with an active IND (Investigational New Drug) application with the FDA for a combustible cigarette as a smoking cessation product.
XXII: 1.12 (+0.02)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process. RAI: 47.38 (+0.07), PM: 98.82 (-0.02), BTI: 123.75 (+0.55), XXII: 1.12 (+0.02), MO: 62.72 (-0.08), ARDM: 5.19 (+0.10), OMER: 11.34 (+0.06)
